Alumis vs Evommune
ALMS and EVMN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALMS and EVMN compare
Alumis is the larger company, worth 2.6 times as much as Evommune ($725M against $277M).
Evommune scores higher on the StockData Score (7 against 6 for Alumis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALMS | EVMN |
|---|---|---|
| Size and price | ||
| Market cap | $725M | $277M |
| Share price | $5.60 | $7.63 |
| Change, 1 year | 6.9% | −60.9% |
| Beta (5Y) | −1.12 | 0.79 |
| Employees | 224 | 48 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 100× | – |
| P/B | 1.9× | 1.1× (better) |
| FCF yield | −44.3% | −32.9% (better) |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Profitability | ||
| Operating margin | −6117% | – |
| Net margin | −5845% | – |
| FCF margin | −4433% | – |
| Return on equity | −111% (better) | −331% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.57 | 8.52 (better) |
| Altman Z-score | −1.67 | 3.85 (better) |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 91.3% | 95.4% |
| Held by insiders | 30.5% | 51.6% |
| Insider net buying, 12 months | $44.7M (better) | −$2.1M |
| Short interest, % of float | 12.3% | 19.3% |
Go deeper
- ALMS stock overview
- ALMS income statement
- ALMS valuation and score
- EVMN stock overview
- EVMN income statement
- EVMN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.